Cardio-oncology for better lymphoma therapy outcomes

Lancet Haematol. 2020 Apr;7(4):e273-e275. doi: 10.1016/S2352-3026(20)30066-1. Epub 2020 Mar 2.

Authors

Wojciech Jurczak¹, Monika Długosz-Danecka², Sebastian Szmit³

Affiliations

¹ Maria Sklodowska-Curie National Institute of Oncology, Krakow 31-113, Poland.
² Maria Sklodowska-Curie National Institute of Oncology, Krakow 31-113, Poland. Electronic address: monika.dlugosz-danecka@lymphoma.edu.pl.
³ Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland.

PMID: 32135129
DOI: 10.1016/S2352-3026(20)30066-1

No abstract available

Publication types

Comment

MeSH terms

Cyclophosphamide
Doxorubicin
Humans
Lymphoma*
Lymphoma, Non-Hodgkin*
Neoplasms*
Prednisone
Rituximab
Vincristine

Substances

Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone